Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses
Abstract Background: shorter duration of symptoms before remdesivir has been associated with better outcomes. Our goal was to evaluate variables associated with the need of ICU admission in a cohort of hospitalized patients for COVID-19 under remdesivir including the period from symptoms onset to remdesivir. Methods: We conducted a retrospective multicentric study analysing all patients admitted with COVID-19 in 9 Spanish hospitals who received treatment with remdesivir in October 2020. The main outcome was the need of ICU admission after 24 hours of the first dose of remdesivir. Results: In our cohort of 497 patients, the median of days from symptom onset to remdesivir was 5 days, and 70 of them (14.1%) were later admitted into ICU. The clinical outcomes associated with ICU admission were days from symptoms onset (5 vs. 6; p=0.023), clinical signs of severe disease (respiratory rate, neutrophil count, ferritin levels and very-high mortality rate in SEIMC-Score) and the use of corticosteroids and anti-inflammatory drugs before ICU. The only variable significatively associated with risk reduction in the Cox-regression analyses was ≤5 days from symptoms onset to RDV (HR: 0.54, CI95%: 0.31-0.92; p=0.024). Conclusion: For patients admitted to the hospital with COVID-19, the prescription of remdesivir within 5 days from symptoms onset diminishes the need of ICU admission..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
ResearchSquare.com - (2023) vom: 17. Okt. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
ALONSO-NAVARRO, Rodrigo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-2273729/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA038109395 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA038109395 | ||
| 003 | DE-627 | ||
| 005 | 20231017132641.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221208s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-2273729/v1 |2 doi | |
| 035 | |a (DE-627)XRA038109395 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-2273729/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a ALONSO-NAVARRO, Rodrigo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background: shorter duration of symptoms before remdesivir has been associated with better outcomes. Our goal was to evaluate variables associated with the need of ICU admission in a cohort of hospitalized patients for COVID-19 under remdesivir including the period from symptoms onset to remdesivir. Methods: We conducted a retrospective multicentric study analysing all patients admitted with COVID-19 in 9 Spanish hospitals who received treatment with remdesivir in October 2020. The main outcome was the need of ICU admission after 24 hours of the first dose of remdesivir. Results: In our cohort of 497 patients, the median of days from symptom onset to remdesivir was 5 days, and 70 of them (14.1%) were later admitted into ICU. The clinical outcomes associated with ICU admission were days from symptoms onset (5 vs. 6; p=0.023), clinical signs of severe disease (respiratory rate, neutrophil count, ferritin levels and very-high mortality rate in SEIMC-Score) and the use of corticosteroids and anti-inflammatory drugs before ICU. The only variable significatively associated with risk reduction in the Cox-regression analyses was ≤5 days from symptoms onset to RDV (HR: 0.54, CI95%: 0.31-0.92; p=0.024). Conclusion: For patients admitted to the hospital with COVID-19, the prescription of remdesivir within 5 days from symptoms onset diminishes the need of ICU admission. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a RAMÍREZ, Margarita |4 aut | |
| 700 | 1 | |a MASIÁ, Mar |4 aut | |
| 700 | 1 | |a PAREDES, Roger |4 aut | |
| 700 | 1 | |a MONTEJANO, Rocío |4 aut | |
| 700 | 1 | |a POVAR-ECHEVERRIA, Marina |4 aut | |
| 700 | 1 | |a CARRATALÀ, Jordi |4 aut | |
| 700 | 1 | |a SALAVERT, Miguel |4 aut | |
| 700 | 1 | |a BERNAL, Enrique |4 aut | |
| 700 | 1 | |a DUEÑAS, Carlos |4 aut | |
| 700 | 1 | |a FLORES, Juan |4 aut | |
| 700 | 1 | |a FANJUL, Francisco |4 aut | |
| 700 | 1 | |a GUTIERREZ, Isabel |4 aut | |
| 700 | 1 | |a RICO, Verónica |4 aut | |
| 700 | 1 | |a MATEU, Lourdes |4 aut | |
| 700 | 1 | |a CADIÑANOS, Julen |4 aut | |
| 700 | 1 | |a BERENGUER, Juan |4 aut | |
| 700 | 1 | |a SORIANO, Alex |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2023) vom: 17. Okt. |
| 773 | 1 | 8 | |g year:2023 |g day:17 |g month:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s12879-023-08222-y |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-2273729/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 17 |c 10 | ||